News

The phase 3 study was a randomized, double-masked, placebo-controlled, multicenter trial evaluating subcutaneous teprotumumab administered every 2 weeks for 24 weeks.

Diana Canto-Sims, OD, kicks off her interview series with a conversation with Kevin J. Kovach, MD, on comanagement.

Images showed that Parkinson disease is associated with a thicker photoreceptor nuclear layer and a thinner layer of photoreceptor processes.

The study demonstrates that Corynebacterium mastitidis, a bacterium that resides on the ocular surface, can be genetically modified to secrete the anti-inflammatory cytokine interleukin-10.

Host Hamza Shah, OD, MS, FAAO, is joined by Raman Bhakhri, OD, FAAO, to discuss geographic atrophy, spurred by Del Priore's paper, "Is geographic atrophy a peripheral retinal disease?"

AlloSpan Canal is designed to address limitations associated with existing approaches by combining nitinol-guided canaloplasty with biological reinforcement.

Sex hormones play important but distinct roles in regulating the ocular surface and adnexal tissues.

This study sheds light on use of the 0.05% atropine, which has been reported to be effective against myopia progression in some but not all studies.

Corticosteroids remain a cornerstone of postoperative management.

The formulation combines 2 pharmacologic agents: carbachol, a direct-acting cholinergic agonist, and brimonidine tartrate, an α-2 adrenergic receptor agonist.

Eye care providers took on dry eye, pediatric eye care, contact lens wear, and more.

Phase 2 ArMaDa data show statistically significant 31% reduction in geographic atrophy lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

Strengthen optometry-ophthalmology comanagement with clear referral vs consultation terminology, smart specialist selection, and efficient communication to improve patient outcomes and grow your practice.

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

Luminopia, formerly cleared by the FDA for amblyopia in children, has begun its foray into IXT with positive data from a preliminary investigation.

China clears first mite-targeting drop for Demodex blepharitis, bringing Xdemvy-style relief and new options beyond lid scrubs and tea tree oil.

Caution is advised by doctors and aviation safety experts.

Michael Raizman, MD, and colleagues evaluated the efficacy and safety of epithelium-on oxygen-enriched corneal CXL in a sub-group analysis of 30 eyes of 22 pediatric patients aged 13 to 17 years.

The study was carried out between July 8 and August 1, 2024, and included 127 eyes from 68 children aged 8–14 years.

QoL areas measured included enjoying relationships/life, overall mood, and time spent thinking of eye pain.

The prospective, multicenter study enrolled 318 patients across 20 US sites.

Erin Rueff, OD, PhD, FAAO, DipAAO, stated that the expanded parameters are set to launch on the lens's 10-year anniversary.

The findings were presented at the 51st Annual Meeting of AAPOS in Boston, Massachusetts.

The expansion follows a 30% year-over-year growth rate.

Explore why near work—not just screens—drives kids’ myopia risk, while silent dry eye worsens early; learn practical habits to boost prevention and compliance.

Meta-analysis finds refraction change better than axial length thresholds for tracking childhood myopia, urging growth-curve AL monitoring to flag retinal risk.